Martin F. Fromm

Friedrich-Alexander-Universität Erlangen-Nürnberg — Germany

Medicine · Health Sciences

72h-index20.5kcitations300works5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Drug Transport and Resistance Mechanisms(147), Pharmacological Effects and Toxicity Studies(91), Pharmacogenetics and Drug Metabolism(51), Amino Acid Enzymes and Metabolism(26), Pharmaceutical Practices and Patient Outcomes(22)

Publications296 total

Strategien zur Verbesserung der Arzneimitteltherapiesicherheit bei oraler Antitumortherapie – das evidenzbasierte AMBORA-Betreuungskonzept
2026
Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the <scp>AMBORA</scp> Cohort: An Analysis of Real‐World Data
Clinical Pharmacology & Therapeutics·2025Open Access
Metabolomic and immunophenotypic signatures in cerebral amyloid angiopathy: a pilot study
Scientific Reports·2025Open Access
A quantitative, broad-panel LC-MS/MS method for the analysis of intact steroid conjugates: A novel approach to steroid profiling for biomarker research in corticoid-dependent diseases
Journal of Pharmaceutical and Biomedical Analysis·2025Open Access
Auswirkungen auf die Arzneimitteltherapiesicherheit und Adhärenz in der Dermato‐Onkologie: Das AMBORA‐Therapiebegleitungskonzept für orale Antitumortherapeutika
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2025Open Access
Putative new biomarkers for renal transporter-mediated drug-drug interactions: Characterization as substrates of organic cation transporter 2, multidrug and toxin extrusion protein 1, and other important drug transporters
Drug Metabolism and Disposition·2025· 2 citedOpen Access
In vitro transporter substrate properties of previously reported biomarkers for renal OAT1/OAT3-mediated drug-drug interactions
Biochemical Pharmacology·2025· 2 citedOpen Access
Implications for medication safety and adherence in dermato‐oncology: The AMBORA care program for oral antitumor therapeutics
JDDG Journal der Deutschen Dermatologischen Gesellschaft·2025Open Access
Transport of the uremic toxin symmetric dimethylarginine (SDMA) by renal transport proteins
Amino Acids·2025· 2 citedOpen Access
Letters to the Editor
Deutsches Ärzteblatt international·2025
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs
Signal Transduction and Targeted Therapy·2025· 12 citedOpen Access
Clinical–pharmaceutical assessment of medication CDSS alerts: content appropriateness and patient relevance in clinical practice
Frontiers in Pharmacology·2025· 1 citedOpen Access
An untargeted metabolomics approach to evaluate enzymatically deconjugated steroids and intact steroid conjugates in urine as diagnostic biomarkers for adrenal tumors
Clinical Chemistry and Laboratory Medicine (CCLM)·2025· 1 cited
Medication safety with oral antitumour therapeutics in paediatrics (youngAMBORA): A mixed-methods approach towards a tailored care program
PLoS ONE·2024Open Access
Physicians' and pharmacists' perspective on clarity and clinical relevance of absolute contraindications in “Summaries of Product Characteristics”
British Journal of Clinical Pharmacology·2024Open Access
Artificial intelligence-powered chatbots in search engines: a cross-sectional study on the quality and risks of drug information for patients
BMJ Quality & Safety·2024· 19 citedOpen Access
Heteroaryl derivatives of suvorexant as OX1R selective PET ligand candidates: Cu-mediated 18F-fluorination of boroxines, in vitro and initial in vivo evaluation
EJNMMI Research·2024· 3 citedOpen Access
Transport of aromatic amino acids <scp>l</scp>‐tryptophan, <scp>l</scp>‐tyrosine, and <scp>l</scp>‐phenylalanine by the organic anion transporting polypeptide (<scp>OATP</scp>) <scp>3A1</scp>
FEBS Journal·2024· 2 citedOpen Access
New Biomarkers for Renal Transporter‐Mediated Drug–Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans
Clinical Pharmacology & Therapeutics·2024· 9 citedOpen Access
Pseudo‐Worsening of Kidney Function Due to Inhibition of Renal Creatinine Secretion: Quality of Information Provided in Prescribing Information/<scp>SmPC</scp>
Clinical Pharmacology & Therapeutics·2024· 3 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Michel Eichelbaum(15), Jörg König(10), Matthias Schwab(9), Mikko Niemi(6), Hartmut Glaeser(6), Elke Schaeffeler(6), Kari T. Kivistö(5), Oliver Burk(5), G. Wilkinson(4), Oliver Zolk(4), Monika Hitzl(4), Richard B. Kim(3), Brenda F. Leake(3), Dan M. Roden(3), Pertti J. Neuvonen(3), Fabian Müller(3), Siegfried Drescher(3), Ulrich Brinkmann(3), Oliver von Richter(3), Janne T. Backman(2)